Effect of Vitamin D Supplementation on Brain Waves in Female Major Depressive Disorder Patients With Hypovitaminosis D

Enrolling by invitation · Not applicable

Conditions studied: Major Depressive Disorder (MDD), Hypovitaminosis D

In brief

Major Depressive Disorder (MDD) is a common mood disorder characterized by persistent sadness, loss of interest and cognitive impairment. Emerging evidence suggests that vitamin D may exert neuroprotective and mood-regulating effects by influencing serotonin synthesis, modulating inflammation and supporting neuronal function. Vitamin D deficiency is frequently observed in MDD patients and has been linked to greater symptom severity and poorer treatment outcomes. Quantitative electroencephalography (QEEG) is a non-invasive tool for assessing brain electrical activity. Alterations in QEEG pattern such as increased theta and reduced alpha power have been reported in patients with MDD , reflecting disrupted cortical processing and emotional regulation. Although interest in the role of vitamin D in mental health is increasing, the direct effect of vitamin D supplementation on QEEG parameters in MDD patients with hypovitaminosis D is not well explored. This study aims to evaluate whether vitamin D supplementation can modulate brain wave activity in female patients with MDD and hypovitaminosis D. Therefore providing insight into its neurophysiological and therapeutic significance.

Key facts

Study ID

NCT07579078

Run by

Bangladesh Medical University

People needed

34

Starts

2026-04-25

Expected to finish

2026-12-01

Last updated by the study team

2026-05-12

Who can join

Age: 20 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• • Diagnosed case of MDD by a psychiatrist form the Department of Psychiatry OPD, based on the Diagnostic and Statistical Manual of Mental Disorder, 5th edition (DSM-V) criteria set by the American Psychiatric Association.
• Hypovitaminosis D ( serum 25 ( OH )D <30 ng/ml )
• Age range : 20-40 years
• Sex: female
• Patients must be on a stable dose regimen, without any changes in drug type or dosage, for at least 6 months prior to enrollment , to minimize confounding effects on EEG outcomes.
• Not receiving any medication that affect central nervous system other than anti-depressant drugs

You may not qualify if…

• Active smokers
• Known hypersensitivity to vitamin D
• Presence of any other serious psychiatric or systemic illness
• Pregnant women
• Lactating women
• Women taking hormonal contraceptives.
• Individuals already taking vitamin D supplements
• Patients with hypercalcemia

Where it is running

• Bangladesh Medical University — Dhaka, Bangladesh

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.